EP16.03-024 Cellworks Singula™ Therapy Response Index (TRI) Identifies Superior OS Outcomes for NSCLC Patients: myCare-203A

      The Cellworks Singula™ TRI was developed to assist clinicians with therapeutic decisions. Cellworks utilizes each patient’s tumor NGS results and Computational Omics Biology Model to biosimulate molecular pathway aberrations and the impact of therapies on restoring normal signaling in patient-specific in-silico diseased cells. For each patient and therapy, Cellworks integrates this multi-omics information into a continuous TRI Score, scaled from 0 to 100 (predicting low to high therapeutic benefit).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Thoracic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect